Indeed, Survivin-based testing, performed on tumor-exosomes, will allow molecular-based diagnosis that in time may also aid in therapy decisions and disease response surveillance leading to better management of prostate cancer. The gene discussed is BIRC5; the disease is prostate carcinoma.